论文部分内容阅读
近年对于子宫内膜异位症(EMs)的基础研究转向其遗传易感性,即基因的差异。过氧化物酶体增殖激活受体γ2(PPAR-γ2)有抑制炎症反应的作用,与脂代谢、糖代谢等有关。PPAR-γ2基因的突变可导致其所编码蛋白构象的改变,从而导致蛋白活性降低,失去对炎症的抵抗作用。研究发现该基因突变与EMs的发生有相关性。PPARγ激动剂可以抑制炎症反应,用PPARγ激动剂治疗EMs的动物实验证实该剂对EMs有效,美国密歇根大学已开始进行该药的临床试验。就PPAR-γ2基因与EMs的关系进行综述。
In recent years, the basic research on endometriosis (EMs) has shifted to its genetic predisposition, that is, genetic differences. Peroxisome proliferator-activated receptor γ2 (PPAR-γ2) can inhibit the inflammatory response, and lipid metabolism, glucose metabolism and so on. Mutations in the PPAR-γ2 gene result in changes in the conformation of the encoded protein, leading to reduced protein activity and loss of resistance to inflammation. The study found that the gene mutation and the occurrence of EMs are related. PPARγ agonists can inhibit the inflammatory response, PPARγ agonist treatment of EMs in animal experiments confirmed that the agent is effective on EMs, the University of Michigan has begun the clinical trials of the drug. The relationship between PPAR-γ2 gene and EMs was reviewed.